Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;40(5):835-842.
doi: 10.1002/hon.3037. Epub 2022 Jun 21.

Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?

Giovanni D'Arena  1 , Alessandro Sgambato  2 , Silvestro Volpe  3 , Giuseppe Coppola  4 , Rachele Amodeo  5 , Virginia Tirino  6 , Fiorella D'Auria  7 , Teodora Statuto  7 , Luciana Valvano  7 , Giuseppe Pietrantuono  1 , Silvia Deaglio  8 , Dimitar Efremov  9 , Luca Laurenti  10 , Antonella Aiello  11
Affiliations
Review

Flow cytometric evaluation of measurable residual disease in chronic lymphocytic leukemia: Where do we stand?

Giovanni D'Arena et al. Hematol Oncol. 2022 Dec.

Abstract

Measurable residual disease (MRD) has emerged as a relevant parameter of response to therapy in chronic lymphocytic leukemia (CLL). Although several methods have been developed, flow cytometry has emerged as the most useful and standardized approach to measure and quantify MRD. The improved sensitivity of MRD measurements has been paralleled by the development of more effective therapeutic strategies for CLL, increasing the applicability of MRD detection in this setting. Chemotherapy and chemoimmunotherapy have firstly demonstrated their ability to obtain a deep MRD. Combined targeted therapies are also demonstrating a high molecular response rate and prospective trials are exploring the role of MRD to guide the duration of treatment in this setting. In this review we briefly summarize what we have learned about MRD with emphasis on its flow cytometric detection.

Keywords: chronic lymphocytic leukemia; flow cytometry; measurable residual disease.

PubMed Disclaimer

References

REFERENCES

    1. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. https://doi.org/10.1182/blood-2017-09-806398
    1. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23-33. https://doi.org/10.1016/j.annonc.2020.09.019
    1. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23(13):2971-2979. https://doi.org/10.1200/JCO.2005.04.021
    1. Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980-988. https://doi.org/10.1200/JCO.2011.36.9348
    1. Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study. J Clin Oncol. 2019;37(4):269-277. https://doi.org/10.1200/JCO.18.01580

MeSH terms

LinkOut - more resources